Kinase inhibitor specialist Sareum develops small molecule therapeutics with application in oncology and autoimmune disease areas. Lead asset SDC-1801 targets the autoimmune space and is nearing an inflection point, with a planned clinical trial application (CTA) filing in mid-2021 and clinical progression in Q421. The other candidate, SDC-1802, is focused on cancer and holds first-in-class promise with value to be unlocked with clinical validation. The out-licensed assets, SRA737 and FLT3+Auror ....
04 May 2021
Sareum Holdings - Treading the TYK2 trail
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sareum Holdings - Treading the TYK2 trail
Sareum Holdings plc (SAR:LON) | 24.2 -0.6 (-9.3%) | Mkt Cap: 24.6m
- Published:
04 May 2021 -
Author:
Jyoti Prakash -
Pages:
17
Kinase inhibitor specialist Sareum develops small molecule therapeutics with application in oncology and autoimmune disease areas. Lead asset SDC-1801 targets the autoimmune space and is nearing an inflection point, with a planned clinical trial application (CTA) filing in mid-2021 and clinical progression in Q421. The other candidate, SDC-1802, is focused on cancer and holds first-in-class promise with value to be unlocked with clinical validation. The out-licensed assets, SRA737 and FLT3+Auror ....